WHAT IS SPRAVATO®?
SPRAVATO® is a form of Ketamine that is FDA approved for the treatment of treatment-resistant depression. It is delivered intranasally, used along with another depression medication, to treat treatment-resistant depression.
WHAT DOES THE TREATMENT ENTAIL?
SPRAVATO® is a prescribed nasal spray that is provided under the direct supervision of a healthcare provider in a certified healthcare setting. Patients will be monitored for two hours following the administration of the drug.
HOW LONG IS MY TREATMENT?
SPRAVATO® is a short-term treatment for treatment-resistant depression. Initial treatment involves two sessions per week for the first four weeks. After the first month, treatment will taper to one session per week for the next four weeks, and then one session every other week.
Kaizen offers two types of services:
- Spravato without Psychotherapy
- Spravato Assisted Psychotherapy during the two hours of monitoring. This has helped our patients to have the best clinical results and get the maximum benefit of the drug
HOW CAN I GET HELP WITH REIMBURSEMENT?
Janssen has been able to provide some assistance through the CarePath Savings Program, which is a rebate program for those with private/commercial health insurance. This program can reduce the cost per dose to $10 per treatment for up to $7,150 worth of treatments. This program does not pay for costs associated with the treatment center fees which may or may not be reimbursable by insurance plans.